Download PDF
Thromb Haemost 1996; 75(06): 902-907
DOI: 10.1055/s-0038-1650392
Original Article
Schattauer GmbH Stuttgart

Increase of Plasminogen Activator Inhibitor Levels Predicts Outcome of Leukocytopenic Patients with Sepsis

R M Mesters
The Department of Internal Medicine, Division of Hematology/Oncology, University of Münster, Germany
,
N Flörke
The Department of Internal Medicine, Division of Hematology/Oncology, University of Münster, Germany
,
H Ostermann
The Department of Internal Medicine, Division of Hematology/Oncology, University of Münster, Germany
,
J Kienast
The Department of Internal Medicine, Division of Hematology/Oncology, University of Münster, Germany
› Author Affiliations
Further Information

Publication History

Received: 16 January 1996

Accepted after revision13 March 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Variables of the fibrinolytic system were prospectively studied in patients with haematologic malignancies in chemotherapy-induced leukocytopenia at onset and during the course of septicemia to evaluate their prognostic value. This group of patients was chosen because of their high risk of developing severe septic complications, thus allowing serial prospective testing of fibrinolytic variables prior to and during evolving sepsis or septic shock. 62 patients with febrile infectious events were accrued to the study. Of these, 13 patients progressed to severe sepsis and an additional 13 patients to septic shock as defined according to standard diagnostic criteria. At onset of fever, plasminogen activator inhibitor (PAI) activity and PAI-1 antigen levels increased from normal baseline levels and were significantly higher in the group of patients who developed septic shock compared to those with severe sepsis (medians: 10.6 versus 1.3 U/ml, p = 0.0001; 50.0 versus 5.0 ng/ml, p = 0.0002). The increase in PAI activity and antigen in septic shock was accompanied by an increase in tissue-type plasminogen activator antigen and total fibrin(ogen) degradation products and a decrease in alpha2-antiplasmin activity (p < 0.006). In contrast, in the group of patients that developed severe sepsis the variables of the fibrinolytic system remained unchanged at onset of fever. These differences between septic shock apd severe sepsis were sustained throughout the septic episode for all variables (p <0.0001). PAI activity of >5 U/ml at onset of fever predicted a lethal outcome with a sensitivity of 92% and a specificity of 100%. Thus, septic shock in leukocytopenia is associated with significant activation of the fibrinolytic system presumably as a response of the vascular endothelium to inflammatory injury. Furthermore, PAI activity measurements are sensitive markers of an unfavourable prognosis.

 

  • References

  • 1 American college of chest physicians/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 20. 864-874
    PubMedGoogle Scholar
  • 2 Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338: 732-736
    CrossrefPubMedGoogle Scholar
  • 3 Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-1389
    CrossrefPubMedGoogle Scholar
  • 4 Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
    CrossrefPubMedGoogle Scholar
  • 5 Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple organ failure syndrome. Arch Surg 1986; 121: 196-208
    CrossrefPubMedGoogle Scholar
  • 2 Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 1992; 101: 816-823
    CrossrefPubMedGoogle Scholar
  • 7 Thijs LG, de Boer JP, de Groot MCM, Hack CE. Coagulation disorders in septic shock. Intensive Care Med 1993; 19: 8-15
    CrossrefPubMedGoogle Scholar
  • 8 Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 1990; 75: 99-102
    CrossrefPubMedGoogle Scholar
  • 9 Hesselvik JF, Blomback M, Brodin B, Mailer R. Coagulation, fibrinolysis, and kalli-krein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-733
    CrossrefPubMedGoogle Scholar
  • 10 Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-1542
    CrossrefPubMedGoogle Scholar
  • 11 Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991; 65: 291-295
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Pralong G, Calandra T, Glauser M-P, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57: 271-278
    CrossrefPubMedGoogle Scholar
  • 14 Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332
    CrossrefPubMedGoogle Scholar
  • 15 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 16 Stief TW, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in the presence of oxidants: a novel principle. Thromb Res 1988; 50: 559-573
    CrossrefPubMedGoogle Scholar
  • 17 Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemor-rhagic disorders. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) J.B. Lippincott Company; Philadelphia, PA: 1994: 1023-1063
  • 18 Van Deventer SJH, Biiller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
    CrossrefPubMedGoogle Scholar
  • 19 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
    CrossrefPubMedGoogle Scholar
  • 20 van der Poll T, Levi M, Biiller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-732
    CrossrefPubMedGoogle Scholar
  • 21 van Hinsbergh VWM, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284-2289
    PubMedGoogle Scholar
  • 22 Silverman P, Goldsmith GH, Spitzer TR, Rehmus EH, Berger NA. Effect of tumor necrosis factor on the human fibrinolytic system. J Clin Oncol 1990; 8: 468-475
    CrossrefPubMedGoogle Scholar
  • 23 De Boer JP, Creasy AA, Chang A, Roem D, Brouwer MC, Eerenberg AJM, Hack CE, Taylor Jr FB. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of escherichia coli. Circ Shock 1993; 39: 59-67
    PubMedGoogle Scholar
  • 24 Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Biiller HS, van Deventer SJH, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal antitissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
    CrossrefPubMedGoogle Scholar
  • 25 Von der Mohlen MAM, van Deventer SJH, Levi M, van den Ende B, Wedel NI, Nelson BJ, Friedmann N, ten Cate JW. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 1995; 85: 3437-3443
    PubMedGoogle Scholar
  • 26 Siebeck M, Spannagl M, Hoffmann H, Schramm W, Fritz H. Time dependent release of tissue-type plasminogen activator and plasminogen activator inhibitor into the circulation of pigs during septic shock. Blood Coagul Fibrinolysis 1991; 2: 459-464
    CrossrefPubMedGoogle Scholar
  • 27 Haj MA, Neilly IJ, Robbie LA, Adey GD, Bennett B. Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leucopenia. Br J Haematol 1995; 90: 541-547
    CrossrefPubMedGoogle Scholar
  • 28 Saito M, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Yoshida T, Aoshima K, Matsuda T. Haemostatic and fibrinolytic parameters in septic patients with leukopenia or leukocytosis. Eur J Haematol 1995; 54: 176-179
    PubMedGoogle Scholar
  • 29 Paramo JA, Perez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64: 3-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Haj MA, Robbie LA, Adey GD, Bennett B. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients. Thromb Haemost 1995; 74: 1528-1532
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
    CrossrefPubMedGoogle Scholar
  • 32 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1989; 260: 11581-11587
    PubMedGoogle Scholar
  • 33 De Boer JP, Abbink JJ, Brouwer MC, Meijer C, Roem D, Voorn GP, Lambers JWJ, van Mourik JA, Hack CE. PAI-1 synthesis in the human hepatoma cell line Hep G2 is increased by cytokines. Evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65: 181-185
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143
    CrossrefPubMedGoogle Scholar
  • 35 Colucci M, Paramo JA, Colleng D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818
    CrossrefPubMedGoogle Scholar
  • 36 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6
    CrossrefPubMedGoogle Scholar
  • 37 Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595-1600
    CrossrefPubMedGoogle Scholar
  • 38 Bevilacqua MP, Schleef RR, Gimbrone Jr MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1985; 78: 587-591
    PubMedGoogle Scholar
  • 39 van Hinsbergh VWM, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and rats in vivo. Blood 1988; 72: 1467-1473
    PubMedGoogle Scholar
  • 40 Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 165-169
    PubMedGoogle Scholar
  • 41 Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989; 74: 222-228
    PubMedGoogle Scholar
  • 42 Paloma MJ, Paramo JA, Rocha E. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase on PAI generation, fibrin deposits and mortality. Thromb Haemost 1995; 74: 1578-1582
    Article in Thieme ConnectPubMedGoogle Scholar